Welcome to our dedicated page for Reshape Lifesciences news (Ticker: RSLS), a resource for investors and traders seeking the latest updates and insights on Reshape Lifesciences stock.
Reshape Lifesciences Inc. (RSLS) is a medical device innovator focused on non-surgical solutions for weight management and metabolic health. This page provides investors and healthcare professionals with essential updates on corporate milestones, product developments, and clinical advancements.
Access timely announcements including regulatory approvals, strategic partnerships, and clinical trial outcomes. Our curated news feed helps stakeholders track the company’s progress in advancing alternatives to invasive obesity treatments and diabetes management technologies.
Key coverage areas include product innovation updates, financial disclosures, and market expansion initiatives. Bookmark this page for structured access to RSLS’s evolving role in the medical device sector, with neutral reporting suitable for both casual observers and professional analysts.
ReShape Lifesciences (Nasdaq: RSLS) announced it will showcase data on its innovative Diabetes Bloc-Stim Neuromodulation (DBSN) device at the Keystone Symposia on Type 2 Diabetes from May 1-4, 2023, in Palm Springs, CA. The DBSN device aims to improve glycemic control in patients with early-stage diabetes by utilizing sub-diaphragmatic vagus nerve neuromodulation. Study results indicate significant improvements in glycemic control, allowing Fasting Plasma Glucose to decrease from an average of 102 mg/dL to 74 mg/dL. A survey showed that 82% of type 2 diabetes patients interested in lifestyle changes would consider a device like DBSN. Paul Hickey, the CEO, emphasized the market potential of this technology, which could reduce dependence on medications and enhance personalized treatment approaches.
ReShape Lifesciences (Nasdaq: RSLS) reported Q4 2022 revenues of $2.7 million, part of a total annual revenue of $11.2 million, down 17.4% from 2021. Despite this decline, the company showed sequential quarterly growth in the U.S. with operating expenses reduced by 27.9% or $5.1 million in the second half of 2022 compared to the first half. ReShape raised approximately $16.0 million over the past year, bolstering its balance sheet and extending its cash runway into 2024. The company is executing a profitability plan, supported by significant product pipeline developments and strategic input from a newly formed Scientific Advisory Board. A patent allowance related to the Obalon Balloon System provides additional protection for its product portfolio.
FAQ
What is the current stock price of Reshape Lifesciences (RSLS)?
What is the market cap of Reshape Lifesciences (RSLS)?
